PatientsVille.com Logo


Miacalcic Medical Research Studies

Up-to-date List of Miacalcic Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Miacalcic Medical Research Studies

Rank Status Study
1 Recruiting Calcitonin for Treating X-linked Hypophosphatemia
Condition: Hypophosphatemic Rickets, X Linked Dominant
Interventions: Drug: nasal salmon calcitonin;   Drug: Saline Nasal Spray Placebo
Outcome Measures: Area under the curve for FGF23;   Area under the curve for serum phosphate and fasting TmP/GFR;   Area under the curve for 1,25(OH)2vitamin D;   Nasal congestion;   Nasal ulceration;   Allergic reactions
2 Unknown  FGF-23 Suppressibility by Calcitonin
Condition: Hypophosphatemia
Interventions: Drug: Calcitonin;   Drug: Placebo
Outcome Measure: A change of 25% in de serum FGF-23 levels in response to a single subcutaneous injection of calcitonin 200 IU.
3 Recruiting Epidural Calcitonin in Lower Limb Amputation
Conditions: Amputation;   Partial Removal of Lower Limb;   Total Removal of Lower Limb
Interventions: Drug: Calcitonin;   Drug: Fentanyl
Outcome Measures: visual analogue scale;   Analgesic consumption
4 Recruiting Pro-calcitonin for Early Detection of Septic Arthritis
Condition: Arthritis, Infectious
Outcome Measure: Septic Arthritis
5 Unknown  The Role of CGRPand Nociceptin in Migraine
Conditions: Migraine;   Headache
Outcome Measure:
6 Recruiting Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: exenatide;   Drug: placebo
Outcome Measures: Determine changes in bone turnover and bone resorption markers during the treatment with a GLP-1 Receptor Agonist (exenatide) compared to placebo in patients with T2DM.;   Calcitonin levels will not vary significantly between periods of treatment with exenatide vs. placebo.
7 Unknown  Pituitary Derived-Intermedin is an Estrogen-Modulated Factor for Reducing Blood Pressure
Conditions: Menopause;   Hypertension
Intervention: Behavioral: intermedin
Outcome Measure:
8 Unknown  Effect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes Mellitus
Condition: Diabetes Mellitus Type 2
Interventions: Drug: Linagliptin;   Drug: Glimepiride
Outcome Measures: Postprandial increase in intact Proinsulin levels (Peak, AUC);   Postprandial Proinsulin/Insulin Ratio;   Fasting intact Proinsulin levels;   Fasting Proinsulin/Insulin Ratio;   Fasting Blood Glucose;   Postprandial Blood Glucose Excursions (Peak; AUC);   Fasting Lipids;   Postprandial Lipids;   Fasting Erythrocyte Flexibility;   Postprandial Erythrocyte Flexibility;   Fasting GLP-1 levels;   Postprandial GLP-1 levels;   Fasting cGMP;   Postprandial cGMP;   Fasting Calcitonin;   Fasting PAI-1 levels;   Postprandial PAI-1 levels;   Fasting ADMA levels;   Postprandial ADMA levels;   Fasting Malonyldialdehyd;   fasting oxidatively modified nucleosides 8-oxodG and 8-oxoGuo;   Hypoglycemic events;   Body Weight
9 Recruiting A Phase 2 Study of GI-6207 in Patients With Recurrent Medullary Thyroid Cancer
Condition: Medullary Thyroid Cancer
Intervention: Biological: GI-6207
Outcome Measures: Calcitonin growth rate kinetics after 6 months of therapy in patients with MTC;   CEA-specific T-cells at 3 months compared to baseline;   Time to progression
10 Not yet recruiting 177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer.
Condition: Thyroid Cancer, Medullary
Intervention: Drug: 177Lu-PP-F11N
Outcome Measures: Phase 0: Scintigraphic visualisation rate;   Phase I: Maximum tolerated dose;   Phase 0: Tumour-to-kidney radiation doses;   Phase 0: Radiation doses;   Phase 0: In vivo stability;   Phase 0: Metabolites;   Phase I: Side reactions;   Phase 1: Biochemical response;   Phase I: Morphological response;   Phase I: Tumour detection rate;   Phase I: Organ radiation doses;   Phase 1: Overall survival;   Phase 1: In vivo stability;   Phase 1: Metabolites
11 Recruiting Vitamin D Supplementation and Male Infertility: The CBG-study a Randomized Clinical Trial
Condition: Male Infertility
Interventions: Drug: Cholecalciferol and calcium;   Other: Placebo
Outcome Measures: semen quality;   sperm motility;   sperm morphology;   sperm concentration;   total sperm count;   semen volume;   Inhibin-B;   Testosterone;   AMH;   estrogen;   LH;   FSH;   SHBG;   DXA scan;   Circulating metabolites of Vitamin D;   PTH;   alkaline phosphatase;   calcium;   phosphate;   FGF23;   Klotho;   osteocalcin;   osteopontin;   Rank-L;   calcitonin;   bone markers;   change in the method of assisted reproductive technique or number of pregnancies;   change in the number of spontaneous pregnancies;   blood pressure;   CYP24A1 expression at the annulus;   Bone and calcium regulators in seminal fluid;   weight and BMI;   Glucose metabolism;   Growth and IGF axis;   tumor markers;   stress hormones;   prolactin;   kidney and cardiovascular markers;   liver markers;   infectious disease;   fever;   inflammatory markers;   natriuretic peptides;   DNA Fragmentation;   Predefined Subgroup analyses
12 Recruiting Effect of Anti-diabetic Drugs on Bone Metabolism and Glycemic Variability
Conditions: Type 2 Diabetes Mellitus;   Menopause;   Osteoporosis;   Osteopenia
Interventions: Drug: Vildagliptin;   Drug: Gliclazide MR
Outcome Measures: Markers of bone remodeling;   Bone mineral density of lumbar spine and femur by X-ray absorptiometry;   Glycemic variability;   Calcitonin
13 Recruiting Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Placebo;   Drug: Dulaglutide;   Drug: Glimepiride
Outcome Measures: Change from Baseline in Glycosylated Hemoglobin A1c (HbA1c) at 24 Weeks;   Change from Baseline in Body Weight at 24 Weeks;   Change from Baseline in Body Mass Index (BMI) at 24 Weeks;   Change from Baseline in Fasting Serum Glucose at 24 Weeks;   Change from Baseline in 7-Point Self Monitored Plasma Glucose (SMPG) at 24 Weeks;   Percentage of Participants Who Achieve HbA1c <7.0% and ≤6.5% at 24 Weeks;   Number of Participants with Reported and Adjudicated Cardiovascular Events;   Number of Participants with Adjudicated Acute Pancreatitis Events;   Change from Baseline in Calcitonin at 24 Weeks;   Percentage of Participants with Self Reported Events of Hypoglycemia;   Percentage of Participants Requiring Additional Intervention for Severe, Persistent Hyperglycemia;   Time to Initiation of Additional Intervention for Severe, Persistent Hyperglycemia;   Dulaglutide Anti-Drug Antibodies;   Change from Baseline in Lipase at 24 Weeks
14 Unknown  Use of Procalcitonin in the Diagnosis of Pleural Effusion
Condition: Pleural Effusion
Outcome Measure:
15 Recruiting Preoperative Biochemical Predictors of Outcome in Patients With Hip Fracture
Condition: Hip Fracture
Outcome Measures: Mortality;   Morbidity
16 Recruiting Botulinum Toxin for the Treatment of Trigeminal Neuralgia
Condition: Trigeminal Neuralgia
Intervention: Biological: Incobotulinumtoxina
Outcome Measures: Difference in mean number of attacks between active and placebo groups;   Difference in mean intensity between placebo and control groups
17 Recruiting A Two-Arm Study Evaluation H.P. Acthar Injection Gel in Treatment of Chronic Migraines
Condition: Chronic Migraine
Intervention: Drug: H.P. Acthar Gel
Outcome Measures: Average total number of headache days (both 40IU and 80IU groups);   Total number of headache days (both 40IU and 80IU groups)
18 Recruiting Body Weight Supported Treadmill Training as Physical Therapy Treatment to Spinal Cord Injury Patients
Condition: Spinal Cord Injury/Damage
Intervention: Procedure: BWSTT (3 days a week for maximum of 20 minutes session)
Outcome Measures: WISCI II;   ASIA standard neurological classification for spinal cord injury patients working sheet;   Modified Ashworth scale;   WHOQOL-BREF;   10-item Modified Barthel Index;   DXA scan;   Full Body DXA scan;   Hematological analysis
19 Recruiting The Comparison Study of Intralesional Botulinum Toxin A and Corticosteroid Injection for Alopecia Areata
Condition: Alopecia Areata
Interventions: Drug: Botulinum toxin type A;   Drug: Triamcinolone acetonide
Outcome Measures: The percentage of terminal hair regrowth after intralesional botulinum toxin A injection;   Possible side effects of intralesional botulinum toxin a injection
20 Recruiting The Biomechanical Effects of Flaccid Paralysis Induced by Botulinum Toxin a After Damage Control Laparotomy
Condition: Damage Control Laparotomy
Interventions: Drug: Botulinum Toxin Type A;   Drug: Placebo
Outcome Measures: The primary objective of this study is to determine whether BTX will facilitate primary fascial closure after DCL.;   Non-invasive biomechanical testing results (surface wave elastography, traction index and durometry);   Mortality;   Duration of mechanical ventilation;   Complications (wound infection, fascial dehiscence, enterocutaneous fistula formation, acute renal failure, pneumonia);   Overall hospital cost;   Total narcotic use (morphine equivalents);   ABPS score

These studies may lead to new treatments and are adding insight into Miacalcic etiology and treatment.

A major focus of Miacalcic research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Miacalcic